JNJ: sales are growing, but what reaches shareholders?

The 60-second read

Five things to know

1. Revenue and earnings diverged. Innovative Medicine grew faster than MedTech, but research spending, transaction costs and mix weighed on profit.
2. Separate the legal charge from the business. The $5.519B litigation adjustment is excluded from adjusted profit; possible settlement cash remains economically relevant.
3. Tremfya replaces much of the Stelara decline. Their combined sales increased only $118M; the rest of the portfolio must keep contributing.
4. The cash story needs the filing. Management estimates more than $6B of quarterly free cash flow, while detailed Q3 cash-flow and balance-sheet tables are still pending.
5. Do not pay for every pipeline success today. The $235 anchor is below the $253.62 dated price; new indications and portfolio changes must earn their valuation.

Three scenarios, one probability-weighted number

Judgmental 12-month values, not price forecasts. Probabilities total 100%.

Signposts: what would change our mind

These are Charged Alpha monitoring thresholds, not management promises. They refer to the continuing parent until legally completed transaction terms establish a new reporting perimeter.

The tape

A dated quote, not a live trading instruction.

The market snapshot is $253.62 per common share and a $611.2 billion equity value. That is about 22.85 times management’s $11.10 adjusted 2026 EPS midpoint and roughly 21.4 times the dated 2027 consensus. The share price is therefore paying for a stable cash franchise and future growth, even though this quarter’s adjusted earnings moved backward. A lower price after a report is not enough to establish that valuation has become attractive.

The current release-day decline was about 5.7%, from $263.73 to $248.61. The October 15 quote had recovered part of that move. Across the nine reports, reactions have differed substantially: revenue growth alone has not dictated the stock’s response. Use the history to test whether expectations were demanding, not as a mechanical prediction of the next report. The price chart also shows why a defensive business can still carry meaningful valuation risk after a strong rerating.

The print

The cleanest comparison is growing sales against falling adjusted earnings.

Johnson & Johnson reported $25.399 billion of sales, up 5.9% from $23.993 billion. Operational growth was 6.0%, and adjusted operational growth was 6.1%. Those are different measures: operational growth removes currency effects, while adjusted operational growth also reflects specified portfolio effects. We retain the reported dollars for the financial model rather than mixing adjusted growth with a reported revenue base.

GAAP earnings were only $210 million, or nine cents a share, versus $5.152 billion a year ago. The legal charge explains much of that dramatic reduction. But removing designated items still leaves adjusted net income of $6.339 billion, down 6.8%, and adjusted EPS of $2.59, down 7.5%. It would be misleading to dismiss the entire earnings decline as a litigation accounting event. The business also has a real cost and mix challenge inside the adjusted result.

A reliable quarter-specific consensus snapshot was unavailable from the subscribed estimates endpoint. We therefore do not label the report an EPS beat or miss using a reconstructed number. The evidence supports the reported year-over-year comparison, the sequential comparison and management’s updated annual range. That distinction matters because an apparent beat can depend on the date and definition of the estimate, especially when acquisitions change which costs analysts exclude.

Segments

Product replacement is working, but it is not free.

Innovative Medicine generated $16.757 billion of revenue, up 7.7%, while MedTech delivered $8.642 billion, up 2.5%. Medicine supplied roughly two-thirds of consolidated sales and most of the dollar growth. This is a diversified healthcare group, but the growth burden is not evenly distributed. The central operating question is whether the next set of medicines can replace patent erosion while supporting attractive research returns.

Darzalex contributed $4.239 billion, or about 25.3% of Innovative Medicine sales. Carvykti, Tecvayli and the Rybrevant/Lazcluze combination also expanded. Those are valuable growth engines, but a broad product list should not obscure concentration: a few successful franchises carry a significant part of the valuation. Product sales measure commercial adoption; they do not by themselves establish treatment volumes, price increases or future clinical success.

Tremfya rose by $972 million while Stelara fell by $854 million, leaving a combined increase of $118 million. This is meaningful replacement progress, yet much smaller than Tremfya’s standalone growth rate suggests. MedTech’s cardiovascular sales increased to $2.307 billion, surgery was slightly lower at $2.528 billion, and vision reached $1.461 billion. Orthopaedics remains part of the reported group and represented about 27.1% of MedTech sales. A future separation changes that perimeter only when its terms and completion are known.

The latest filed segment-profit table is Q2: Innovative Medicine earned $6.249 billion before tax and MedTech $1.177 billion on the company’s segment measure. These are not Q3 estimates and do not equal consolidated GAAP pretax without unallocated items. We show the dated series to understand the economics of the two businesses, while leaving the current quarter blank until the filing supplies the actual allocation.

Profit bridge

A large adjustment does not erase an economic obligation.

The quarter’s $34 million of GAAP pretax income becomes $7.672 billion after the company’s designated pretax adjustments. The largest is $5.519 billion of litigation expense. Other adjustments include $1.240 billion of intangible amortization, $339 million of in-process research impairments, $369 million related to the Orthopaedics separation and $195 million of restructuring-related costs. Acquisition and integration adjustments were a net $34 million credit, so they reduce rather than increase this bridge.

The tax line is a $176 million benefit against just $34 million of pretax income. Dividing those two produces a negative 517.6% GAAP effective rate, a mathematically correct but economically unhelpful run-rate assumption. The adjusted rate is 17.4%. Neither the GAAP benefit nor the litigation add-back should be capitalized as recurring operating improvement. The earnings route uses a dated adjusted consensus and is checked against cash rather than assuming that every excluded cost is irrelevant.

The company describes a proposed $5.5 billion ovarian-talc resolution conditioned on at least 95% participation in remaining claims. A booked expense and a cash payment are different events. The charge is already reflected in reported profit; the future timing, conditions and funding matter for shareholder cash. We do not subtract the same charge from both earnings and valuation indiscriminately, but we also do not present adjusted profit as if the associated obligation disappears.

Earnings quality

The same nine tests, with unavailable data left unavailable.

Intangible amortization is noncash in the current period, but the acquisitions that created those assets cost real money. Adding amortization back can help compare current operating activity; it does not prove that the original purchase price earned an adequate return. The same caution applies to repeated portfolio charges. A sequence of individually unusual costs can become a persistent burden for an acquisitive company.

The cash-conversion chip remains unavailable for the exact quarter because management’s free-cash-flow estimate does not provide the full operating-cash reconciliation. Receivables and inventory are shown through Q2 only. We do not manufacture a current accruals score or a fraud-screening statistic from mixed dates, nor treat an unavailable score as a pass. The useful next check is the filed cash statement: identify litigation payments, acquisition effects and working-capital movements before judging whether the earnings rebound is durable.

Cash and balance sheet

Strong recurring cash, substantial competing uses.

Operating cash flow was $24.530 billion in 2025 and capital expenditure was $4.832 billion, leaving $19.698 billion of free cash flow. That was slightly below 2024’s $19.842 billion despite higher operating cash flow, because investment spending increased. The three-year history supports the existence of a large cash engine. It does not support treating every dollar as available for buybacks, since dividends, acquisitions, debt management and legal obligations compete for that cash.

Management estimates approximately $17 billion of cash and marketable securities and $45 billion of debt at the end of Q3, or roughly $28 billion of net debt. The latest detailed filed balance sheet is June 28: cash and investments of $20.758 billion, debt of $49.036 billion and equity of $84.971 billion. These dated figures are not interchangeable. We use the rounded Q3 figures for a current leverage discussion and the filed Q2 values for receivable, inventory and liability detail.

The 2025 dividend and repurchase outlays totaled $18.334 billion before acquisitions. Acquisitions used another $17.541 billion, illustrating why recurring FCF does not by itself describe the financing need. The 2026 FCF guide of approximately $21 billion is encouraging, but legal settlement timing and future deal spending remain separate claims on that capacity. Our cash valuation begins with this recurring guide and explicitly treats exceptional cash uses as uncertainty rather than hiding them in an unexplained multiple.

Valuation

Three routes converge near $234; the rounded anchor is $235.

We value the continuing parent common share in U.S. dollars. The DCF uses an equity cash-flow convention: operating cash flow less capital expenditure is already after the interest burden embedded in CFO. We therefore discount it at an equity required return and do not subtract net debt a second time. This is a deliberately transparent recurring-cash model, not a full acquisition-financing model. A material settlement payment or new deal could reduce the cash available to shareholders and would require an explicit update.

Eight percent explicit cash growth assumes that replacement medicines and MedTech execution can grow distributable cash faster than a mature low-growth pharmaceutical basket. The matching 8% required return reflects the franchise’s resilience without treating it as a bond. Three percent terminal growth is below the explicit period and assumes long-run reinvestment sustains a durable business. None of these is an issuer forecast. The grid shows how quickly value falls if the required return rises or long-run growth disappoints.

The simple mean of the three routes is $233.81, rounded to a $235 anchor. The scenarios deliberately span $190 to $285, and their weighted value is $236.25. These are distinct outputs. At $253.62, the anchor implies about 7.3% downside before dividends. With high uncertainty, a 20% discount to the anchor would put a stronger entry margin near $188. That is a valuation discipline rather than a forecast that the stock must trade there.

The market-implied test is demanding even without a reverse model: the price asks investors to accept only about a 3.44% yield on the approximately $21 billion FCF guide, with growth doing the rest. Our 8%/8%/3% cash model produces less than the market price. To justify more, an investor needs higher sustained cash growth, a lower required return or a more generous terminal assumption. It is reasonable to believe in the pipeline; the unresolved question is how much of that success has already been paid for.

Versus Wall Street

Compare like dates and definitions before comparing targets.

The broad Street average is above our anchor, while several dated post-print entries are lower than that broad average. This is not proof that every analyst is cutting estimates: the sample and dates differ. We prefer the specific fresh entries for a fair comparison and retain the consensus range as context. Our lower value comes primarily from a cash-based cross-check and a more restrained treatment of portfolio risk, not a claim that the commercial growth drivers are fictitious.

The current 2026 revenue consensus is about $101.22 billion, close to the company’s $101.2 billion reported midpoint. The 2027 EPS estimate of $11.85 is not official company guidance. Management has already flagged $1.36 per share of combined 2027 dilution from Firefly Bio and Sail Biomedicines. We do not subtract that amount again from consensus without knowing what analysts incorporated, but we treat the assumption as a specific item to test at the next guidance update.

Management scorecard

Reward quantified progress; distinguish plans from completed outcomes.

Management raised and narrowed its annual outlook while acknowledging an unfavorable near-term mix of costs. The guidance change is small relative to the size of the business: the reported sales midpoint increased by $100 million and adjusted EPS by six cents. Those increases are useful evidence of confidence, but they should be weighed against the actual current-quarter adjusted decline. We would give more credit to a sustained improvement in cash returns than to a higher adjusted target by itself.

The intended DePuy Synthes separation remains an analysis topic, not a reason to exclude the continuing parent from coverage. Management is evaluating alternatives and says it is leaning toward a spin. There is no basis here to assume final distribution ratios, proceeds, retained debt or tax treatment. A sum-of-parts calculation that assigns the entire separation benefit today while leaving every current earnings dollar in the parent would double count value. Our present model keeps the reported perimeter and flags the future change.

1. How much of the approximately $21B FCF guide will remain after separately identified legal payments and transaction cash uses?
2. What precise assumptions support the $1.36 per-share 2027 deal dilution, and when should the acquired programs begin generating returns?
3. Can Tremfya plus Stelara sustain combined growth while other immunology products decline?
4. What debt, pension, tax and stranded-cost allocations will accompany a DePuy separation?
5. When will adjusted margin improvement translate into higher per-share cash flow rather than only a larger list of exclusions?

The annual filings report approximately 131,900 employees for 2023, 138,100 for 2024 and 138,200 for 2025. The provider profile carries a different current number, so the historical table uses the filings and does not imply a like-for-like productivity gain from mixed dates. Acquisitions can expand both sales and staffing. Management’s capital-allocation record should be judged on returns after those investments, not simply on the number of programs added to the pipeline.

Risks

The valuation must survive a less favorable path.

The bull case deserves a fair hearing. Oncology and immunology growth can outweigh erosion, the group can fund innovation from substantial internal cash, and a well-designed separation could sharpen accountability. If the new portfolio produces better growth and returns while legal uncertainty declines, a premium multiple can be justified. The bull scenario is not merely a higher target; it requires those operating and cash conditions to occur together.

The bear case is more than a litigation headline. Adjusted profit can remain under pressure even after the special charge falls away. Acquisition dilution, research spending, pricing constraints and slower replacement growth could leave per-share cash growth below what the stock already discounts. A separation can also create costs or reduce diversification before delivering benefits. Under that path, a lower multiple and lower sustainable earnings reinforce each other.

Our HOLD conclusion sits between those cases. The business has real strengths and a long cash-generation record, but the current price offers limited room for several uncertainties to resolve unfavorably. This is a valuation judgment with medium conviction, not a declaration that the company is broken or that every transaction destroys value. New filed cash data, clearer separation economics or a materially different price can change the conclusion.

Catalysts

Watch the evidence, not an assumed closing date.

These are evidence windows, not promises of price catalysts. A scheduled presentation may add little financial detail; a filing can matter more even when it attracts fewer headlines. We will first reconcile the missing quarter cash and segment tables, then test the full-year cash outcome and the assumptions embedded in 2027 estimates. The price reaction belongs after that assessment, rather than substituting for it.

Appendix

Source tables, units and methods.

All statement amounts below are USD millions unless a row says EPS, shares or percentage. Quarter-end dates follow the issuer’s fiscal calendar, not provider calendar-quarter labels. Nine earnings exhibits supply the income and revenue series; filed quarterly and annual reports supply balance sheets and segment pretax history. Current-quarter fields that the release does not disclose remain unavailable. Derived values are computed in the companion dataset and build script.

Structure and methods: JNJ is the NYSE-listed U.S. common share, not an ADR, and no ADS conversion is used. The annual auditor is PricewaterhouseCoopers LLP. No VIE or dual-class discount is inserted without an identified structure requiring one. The market-implied share count is market capitalization divided by the same dated price; diluted shares are weighted-average earnings denominators. The DCF is an equity cash-flow model, while net debt is shown separately as a balance-sheet risk. Product concentration is disclosed through the named-franchise revenue table; product sales do not establish customer concentration.

The income exhibit’s cost of products sold includes intangible amortization. A provider classification that removes it would overstate the GAAP gross margin used here. Similarly, debt amounts are taken from the actual balance-sheet carrying-value rows rather than rounded debt-note tags. FCF is CFO less capital spending; FCF less SBC is an additional economic-cost lens, not a GAAP measure. Working-capital days use ending balances and a 91-day convention. The current quarter’s detailed cash-flow statement and segment-profit note are pending, so the packet does not manufacture an accruals, Beneish or Altman result from inconsistent periods.

Glossary: reported growth includes currency; operational growth removes currency; adjusted operational growth also reflects specified portfolio changes. IPR&D is in-process research and development. A pretax adjustment and its tax effect must both be included to reconcile adjusted net income. A target price is an analyst opinion at a date, not a guaranteed outcome. A planned spin is not a completed distribution. Our scenarios are judgmental conditional values, and their probabilities are not statistical estimates from the nine-report reaction sample.

Source hierarchy: actual issuer and SEC filing tables control financial classification and period identity. Provider data supplies market context and a cross-check, not a substitute when it conflicts with a filing. Historical source bodies, extraction tables and hashes are retained with the episode. Quarterly analyst estimates were unavailable under the subscription; a news row with conflicting attribution was excluded. No closed historical episode was reopened to construct this review. The current packet establishes explicit signposts for a later comparable review rather than inventing an earlier forecast record.